Mesenchymal stem cell therapy in human disease: Advances toward cure, prevention, and overcoming translational barriers
Year: 2025
Type: article
Abstract: Mesenchymal stem cells (MSCs) are the most versatile regenerative cells in current regenerative medicine, with applications ranging from immune disorders to degenerative and inflammatory diseases. The past few decades have primarily focused on their differentiation into mesodermal tissues; however, MSCs are now being explored for their far more clinically relevant paracrine, immunomodulatory, anti-inflammatory, and tissue-repairing functions.[1,2] Isolated from various sources such as bone marrow, adipose tissue, placenta, and umbilical cord, MSCs can home to sites of injury, modify immune responses, and organize microenvironmental repair through the release of extracellular vesicles (EVs), cytokines, and growth factors.[3,4] BIOLOGICAL FOUNDATIONS OF MESENCHYMAL STEM CELL THERAPY MSCs utilize their therapeutic effects mainly via secretome-driven mechanisms involving soluble molecules, anti-apoptotic factors, angiogenic signals, and EVs/exosomes rather than their long-term engraftment.[3] They alter T-cell activation, suppress NK-cell cytotoxicity, control B-cell function, and alter macrophage polarization toward anti-inflammatory M2 phenotypes.[1,2] These characteristics describe their usefulness in diseases illustrated by immune dysregulation, chronic inflammation, or inadequate endogenous repair. Their short-lived tenacity in vivo emphasizes their role as biological response modulators, fine-tuning pathologic environments instead of replacing tissue. CLINICAL SUCCESS OF MESENCHYMAL STEM CELLS IN THERAPY Clinical translation of MSCs has given many favorable outcomes across numerous disease areas, which have received regulatory approval. Immune and inflammatory diseases/disorders The most significant clinical accomplishments for MSCs are their success in steroid-refractory acute graft-versus-host disease. Many clinical trials have shown high response rates and enhanced survival, prompting regulatory approval of TEMCELL® in Japan.[4] MSCs reestablish immune homeostasis by decreasing cytokine storms, lessening T-cell activation, and restoring immunologic balances. Another landmark is the approval of darvadstrocel for complex perianal fistulas in Crohn’s disease, after the landmark ADMIRE-CD Phase III trial that has shown superior remission outcomes compared with placebo.[5] Beyond approved uses, MSCs demonstrate fruitful results in autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Clinical trials have shown a reduction in inflammatory markers, better disability indices, and stabilization of disease progression.[2] Regenerative and musculoskeletal applications In knee osteoarthritis, MSCs have persistently demonstrated an improvement in pain and functional outcomes. A few trials recommend structural advantages such as increased cartilage thickness, supported by magnetic resonance imaging and biochemical markers.[6] MSCs’ anti-inflammatory, chondroprotective, and trophic effects provide symptomatic advantage and potential disease modification. Orthopedic applications, which include nonunion fractures, tendon injuries, and cartilage defects, have also demonstrated potential outcomes through MSC-enhanced regeneration and matrix repair.[4] Neurological and cardiovascular diseases MSC-based treatments in stroke, Parkinson’s disease, and spinal cord injury have demonstrated enhancements in functional neurological characteristics, decreased lesion burden, and increased neurotrophic factor expression.[7] These effects are primarily MSC-driven modulation of neuroinflammation and promotion of angiogenesis and neuronal survival. In cardiovascular disease, MSCs have been examined for myocardial infarction and heart failure, which have improved perfusion, reduced scar formation, and enhanced ventricular function in early-phase trials.[7] Pulmonary and infectious disease applications The COVID-19 pandemic has also shown interest in MSCs due to their capability to decrease uncontrolled inflammation. Meta-analyses have shown significantly reduced mortality, enhanced oxygenation, and attenuated cytokine levels in MSC-treated acute respiratory distress syndrome patients.[8] BARRIERS AND OBSTACLES IN MESENCHYMAL STEM CELL-BASED THERAPY Despite established successes, numerous barriers impede the broad, consistent clinical utilization of MSC therapies. Product heterogeneity is the main challenge: MSCs vary widely depending on donor bioparameters, tissue origin, culture conditions, passage number, and cryopreservation practices, leading to unpredictable therapeutic potency across studies.[9] Considering this, there is no unanimously certified potency assay capable of predicting in vivo efficacy, making standardization and regulatory assessment tough. The MSC immunomodulation is well established, and the pinpointed molecular pathways accountable for clinical benefit vary across diseases and patient populations. This affects heterogeneity in dosing, timing, delivery route, and clinical endpoints in trials. In addition, MSCs have restricted survival and engraftment after administration, which may lead to short-lived effects that require enhanced engineering strategies. Regulatory barriers persist, with different countries adopting varying frameworks for cell therapies, complicating global trial harmonization. Temporarily, the rise of unregulated stem-cell clinics providing undocumented treatments impedes scientific rigor and patient safety and risks undermining legitimate therapeutic progress. FUTURE PROSPECTS Genetically engineered MSCs, designed to overexpress therapeutic cytokines, chemokines, or homing receptors, are currently receiving significant attention for refining their potency and disease-specific targeting. Preconditioning or licensing strategies, exposure to inflammatory cytokines, hypoxia, or small molecules can further improve MSC immunomodulatory function and survival before administration. Major progress will come from MSC-derived EVs, including exosomes, which provide cell-free, stable, low-immunogenic therapeutic alternatives that preserve MSC bioactivity while limiting many safety and regulatory restrictions of live-cell therapy.[3] Comprehensively, these inventions will permit MSC therapy to transition from a promising experimental intervention to a robust, mainstream clinical modality capable of treating some of the most refractory diseases of the century.
Authors: Shailendra Dwivedi, Akash Bansal, Anand Mohan Dixit
Institution: All India Institute of Medical Sciences Gorakhpur
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7117355335